Surely, Pristine Solutions (PRTN) would have wanted to end the trading leading in both trades and dollar volume for all penny stocks off the news of their baby steps towards faking an FDA approval. However, going into the last few minutes f trading, the dollar volume leader in penny land is Northwest Biotherapeutics, Inc. (NWBO) on their 2nd largest share volume session ever. Since their biggest session on the 6th of August when shares reached 0.523, NWBO stock has plunged -36.9% on the heels of their Phase III clinical trial for Brain Cancer in both the U.S. and Europe.
Our New Alert Is Set For Mid-September! Click HERE To Make Sure You Don’t Miss It!
NWBO Stock Chart
Close: 0.33, down -0.0201 (-5.74%)
Dollar Volume: $2,403,540
Average Trade Size: 35,136
Issued and Outstanding: 175,871,162
Looking for Hot Penny Stocks? Click here and get Alerts on the Best Penny Stocks FREE
Investor’s are not showing the optimistic view on NWBO stock that one non-affiliated investor displayed just two weeks ago. On August 17, 2012, the Company entered into a Note Purchase Agreement in the principal amount of $1,105,000 which can be converted into shares at $1.25 per share. That’s 278.79% higher than Thursday’s closing price.
The month began for the biotech with them amending certain agreements to double the production capacity in the U.S. for the Company’s DCVax®-L immune therapy for Glioblastoma multiforme patients. With manufacturing also powering up in Europe, production is already fully operational in Germany, and was in the final stages of preparation in the U.K. as of the 7th of August.
Northwest Bio had approval in hand two weeks ago from the Medicines and Healthcare Products Regulatory Agency of the U.K., the U.K.’s version of the FDA, for the planned 300-patient Phase III clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme brain cancer to proceed. Coupled with the preexisting U.S. trials which are underway in 41 sites across the country, NWBO should be experiencing a bullish sentiment.
The $430, 000 in revenues for the three months ended June 30th was a 1,691% increase in quarterly revenues compared to the $24,000 reported for the three month period ended December 31, 2011. Another reason to question why NWBO Stock is experiencing such bearish sentiment. Without being able to wrap my head around this, it’s on the list of penny stocks to research fully over the long upcoming weekend for a better understanding.
About NWBO Stock
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.
Since 2004, Toucan Capital Fund II, L.P. , Toucan Partners LLC, entities controlled by Ms. Linda Powers, the managing director of Toucan Capital and managing member of Toucan Partners, and Ms. Linda Powers, CEO and Chairman of Northwest Biotherapeutics Inc., have provided substantial funding to the Company. During the period from 2004 to 2007, the funding consisted of various loans and the purchase of common stock.
Under a Conversion Agreement during 2007, all loans payable to Toucan outstanding at the time were converted to preferred stock and the preferred stock was subsequently converted to common stock. As a result of additional loans, as of June 30, 2012, notes payable include $4.3 million convertible notes payable to Toucan.
The notes payable to Toucan outstanding as of June 30, 2012, are convertible at prices ranging from $0.20 to $0.57.
As of June 30, 2012, Toucan held 71,202,148 shares of NWBO stock, roughly 43% of the shares outstanding as well as beneficial owner, including unexercised warrants, of 120,558,957 shares of NWBO stock, representing a beneficial ownership interest of roughly 56%.
Bottom Line: NWBO led all penny stocks in dollar volume Thursday in an epic trading session for shares traded, the second largest in the last three years. Is Thursday indicative of further high volume trading sessions to follow? We will just have to wait and see.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share